A carregar...
The Design and Evaluation of an l-Dopa–Lazabemide Prodrug for the Treatment of Parkinson’s Disease
l-Dopa, the metabolic precursor of dopamine, is the treatment of choice for the symptomatic relief of the advanced stages of Parkinson’s disease. The oral bioavailability of l-dopa, however, is only about 10% to 30%, and less than 1% of the oral dose is estimated to reach the brain unchanged. l-Dopa...
Na minha lista:
| Publicado no: | Molecules |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MDPI
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6150007/ https://ncbi.nlm.nih.gov/pubmed/29186917 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/molecules22122076 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|